



Aging
Analytics
Agency

Mitochondria-Longevity Research in Switzerland

Special Analytical Case Study

Q3 2021

Table of Contents

Introduction	2
Approach of the Report	3
Executive Summary	4
General Overview	7
Mitochondrial Dysfunction Among Other Hallmarks of Ageing	8
Age-Related Approach	9
Mitochondria in Ageing: Avenues/Directions	10
Mitochondrial Clinical Trials vs. Ageing Clinical Trials	11
Growth of Scientific Interest in the Role of Mitochondria in Ageing	12
Mitochondria Treatment Targets	13
Diagnostic Biomarkers	14
Mitochondria in Longevity: Switzerland Overview	15
Leading Companies in Mitochondria-Longevity Industry	16
Investment Activity in the Industry	24
Fundamental Research of Mitochondrial Dysfunction	25
Key Influencers and Experts	26
Trends and Prospects of the Mitochondria-Longevity Industry in Switzerland	27
Future Opportunities in Advancing Mitochondrial Medicine	29
Conclusions	30
Disclaimer	35

Mitochondria-Longevity Research in Switzerland Q3 2021 was compiled to give a detailed systematic description of the **innovative approaches for regulating mitochondrial function to control Human Longevity and treat some systemic disorders**. This analytical case study focuses on **BioTech, Pharmaceutical and Healthcare companies**, and **R&D institutions in Switzerland** and their partnerships, predicting the development of the relevant market and determining the degree of technology relevance. In addition, a unique database was compiled for the systematic review of key stakeholders in the industry.

All the technologies described in the analytical case study are already available, in use, and ready for further research.

The Mitochondria Targets and Biomarkers are selected by their **clinical efficacy** and create the most relevant modern precedent for safe and effective human experimentation and validation that the Longevity Industry can apply.

The separate chapter of the report is devoted to the **overview of companies in Switzerland** (for example, **Amazentis**) that are developing different technologies to enhance the mitochondrial longevity capacity. Overall, this analytical case study offers **a one-stop expert evaluation of a novel and dynamic industry**, particularly in Switzerland, with high growth potential.

Approach of the Report

Database

100+
Companies

120
Investors

30
R&D Centres

The database was formed based on:

- the **identification of companies** that conduct or have conducted ageing and mitochondria-related clinical trials or preclinical studies;
- the **determination of investors** that contributed money to these companies.

Applied Research and Analytics Methods

Descriptive
Analysis

Mixed Data
Research

Data
Triangulation

Comparative
Analysis

Qualitative Data
Collection

Data
Filtering

Data Sources

Media Overview
(Articles and Press Releases)

Industry-Specialised
Databases

Publicly Available Sources
(Websites)

Industry Reports and
Reviews

Relying on various research methods and analytics techniques, the analysis provides a comprehensive overview of the Preclinical and Clinical Trials Industry. This approach has certain limitations, especially when using publicly available data sources and conducting secondary research. Aging Analytics Agency is not responsible for the quality of the secondary data presented herein; however, we do our best to eliminate the said risks using different analytics techniques and cross-checking data. Please note that we did not deliberately exclude certain companies from our analysis. Nor was it due to the data-filtering method used or difficulties encountered. The main reason for their non-inclusion was incomplete or missing information in the available sources.

Executive Summary

Ever since being discovered, **mitochondria – which provide the body with its main source of energy** – have played a key role in understanding human biology. Because of their importance in cellular physiology, defects in mitochondria are associated with various human diseases. In addition, many studies have shown that mitochondria play a central role in ageing.

Switzerland is one of the best and **most innovative locations for biotechnology in Europe**. Local companies hold leading positions throughout many sectors and thus attract capital and researchers worldwide. Furthermore, the economic and scientific environment boasts the presence of successful international chemical and pharmaceutical companies, such as **Novartis** and **Roche**, as well as innovative firms from the medical technology, biotechnology, and nanotechnology sectors, for example, **Amazentis**, making it highly suitable for strategic partnerships, licensing, or patent sales.

Main Features of the Analytical Case Study

Overview of Clinical Trials for Mitochondria at All Phases

In-depth Review of Notable Mitochondrial Trials for Ageing


Detailed Analysis of Key Market Players in Switzerland

Trends and Prospects of Mitochondria-Longevity Industry in Switzerland

Key Expert Findings of a Novel and Dynamic Industry with High Growth Potential

Swiss Companies
by Field of Operation
Q3 2021

Anti-ageing - 3
Others - 4



General Overview

Q3 2021



Mitochondrial Dysfunction Among Other Hallmarks of Ageing

Genomic Instability

Ageing can be the consequence of increased DNA damage accumulation. This is due to physical, chemical, and biological agents, as well as DNA replication errors, spontaneous hydrolytic reactions, and reactive oxygen species (ROS).

Telomere Attrition

Telomeres are the chromosomal regions located on the ends of chromosomes. They tend to become increasingly shorter after each DNA replication. When this sequence ends, the cell dies. Telomerase deficiency in humans is associated with age-related diseases.

Epigenetic Alteration

Epigenetic changes involve alterations in DNA methylation, post-translational modification of histones, and chromatin remodelling.

Loss of Proteostasis

Proteostasis involves mechanisms for the stabilization of correctly folded proteins, and the heat-shock family of proteins, as well as mechanisms for the degradation of proteins. These processes tend to change during ageing.

Deregulated Nutrient Sensing

Nutrient sensing includes trophic and bioenergetic pathways, such as insulin and IGF-1, signaling pathways, and other systems (mTOR, AMPK, and sirtuins).

Mitochondrial Dysfunction

There is a noticeable reduction in ATP generation and increased electron leakage in the respiratory chain caused by ageing.

Cellular Senescence

Cellular senescence can be defined as a stable arrest of the cell cycle. The accumulation of senescent cells in aged tissues can lead to age-related disease progression.


Stem Cell Exhaustion

Stem cells are cells from which all other cells with specialized functions are generated. There is a substantial decrease in the number of stem cells during life. Recent studies suggest that stem-cell rejuvenation may reverse the ageing phenotype.

Altered Intercellular Communication

Neurohormonal signaling tends to be deregulated in ageing as inflammatory reactions increase, while immunosurveillance against pathogens and premalignant cells declines.

Ageing-Related Approach



While analysing the role of mitochondria in Longevity, it's crucial to understand the scope and impact of the aforementioned companies.

Factors include the number of existing companies within the Longevity Industry and the percentage of mitochondria-based programmes.

As of **Q3 2021**, there are more than **300 programmes targeting ageing** as a root cause of disease and not as a symptom, comprising **\$58.5B** in market capitalisation. Experts predict that the global anti-ageing market will reach a value of **\$88.30B** by 2026.


Nowadays, approximately **9.5% of anti-ageing programmes** address a major hallmark of ageing — **mitochondrial dysfunction**, with a total capitalisation volume of around **\$5.5B** in value.

Mitochondria in Ageing: Expansion Avenues / Directions

The BioTech industry is affected less than most by the market and logistical consequences of the COVID-19. **BioTech companies and startups in particular just keep working through market downturns** and disruptive events, and are largely only impacted to the degree that they need to raise funding. Progress continues apace. **Mitochondria targeting approach have produced robust results in Ophthalmology.** The first human trials have been completed with promising results, and more are in progress.

The most direct and indirect approaches of mitochondria targeting are under active development, such as mitochondrial antioxidants, mTOR inhibitors, NAD+ enhancers and so on. They are essentially attempting to make the aged metabolism more resilient to underlying damage, or **override some of its reaction to damage, without actually repairing that damage.**


Mitochondria Pipeline: 100+ Programmes, 100+ Companies




Note: There are low numbers of clinical trial in Phase 1 due to their cancelation during the COVID-19.

Mitochondrial Clinical Trials vs. Ageing Clinical Trials

Total Number of Mitochondrial Clinical Trials (630 trials)



Share of Mitochondrial Trials in Ageing (2,100 trials)




As of 2021, the percentage of clinical trials related to mitochondrial dysfunction is **negligible compared to trials focused on other hallmarks of ageing (~3% of the total amount)**. Of these, only 16% have reached Phases 3 and 4, the stages at which industry-ready products are feasible in the near future.

Only **15 clinical trials** for study of mitochondrial function are provided **in Switzerland for the last 10 years**: 8 trials for therapeutic programs, 3 - dietary supplements, 3 - behavioral study.


Growth of Scientific Interest in the Role of Mitochondria in Ageing

Total Scientific Interest in the Role of Mitochondria in Ageing



Broadly speaking, scientific interest in the role of mitochondria in ageing is now 10 times greater than it was in the early 2000s. **The most reliable mitochondrial biomarkers**, such as concentration of **amino acids, creatinine level, lactate and SOD** in biological samples, are a “golden standard” for clinical trials. The **new diagnostic biomarkers** are **GDF15 and FGF21**. The other one is **miRNA** which used for diagnostic of mitochondrial disease (TamiRNA). Among the newest mitochondrial therapeutic targets, **the most promising** are **TSPO** for imaging and **SIRT1** and **mTOR** for regulation of energetic processes.

Popularity of Mitochondrial Targets / Biomarkers in Time



Search Terms

Keywords: “target name” + ageing
Article Type: Clinical Trials

Mitochondria Treatment Targets

Energetic Processes

AMPK DOHD GIP ATPase ND1

ICT KATP PARP delta Prostaglandin-E

mTOR(1,C1) NAD+ NNMT SIRT1

Apoptosis

BCL-XL BCL-2 ROS

foxo4-p53 FOXO p53

HIF1 ERR

Mitochondrial Dynamics

USP 30 LRRK2 DJ1 MCS

HSP90 HSP27 HSP 70

PINK1 OMA1 SGLT2

Reactive Oxygen Species

NOX1 NOX2 NOX4 ROS

SOD Frataxin STAT3

NOS II NF-E2

Oxidative Phosphorylation

Mitochondrial uncouplers

FRX ACC GLP1R

Mitochondrial pyruvate carrier

Treatment products



Treatment products



Treatment products



Treatment products



Treatment products



Note: Therapeutic target medicines that are in development or are currently on the market are presented here. It is evident that energetic processes are the primary focus of study and development. Other fields are actively growing, but because of the high complexity, most of them are not yet marketed.

Diagnostic Biomarkers

Mitochondrial Genetics

Single nucleotide polymorphisms
Deletions Gene expression Insertions
Mitochondrial DNA copy number

Biomarkers products, tests, panels



Metabolic Biomarkers

Lactate Pyruvate Orotic Acid
Beta-Hydroxybutyric Acid
Carnitine Acylcarnitine Creatine
Fatty Acids Organic Acids Amino Acids

Biomarkers products, tests, panels



Oxidative Phosphorylation

Pyruvate dehydrogenase complex
Complex I-V H+ (proton) leak
Endpoint relative mitochondrial membrane potential
Dynamic changes in relative mitochondrial membrane potential

Biomarkers products, tests, panels



Mitochondrial Dynamics

Mitochondrial outer membrane integrity
Mitochondrial permeability transition
Muscle biopsy examination Cardiopilins

Biomarkers products, tests, panels



Energetic Process

ATP-linked respiration ADP/ATP ratio
Maximal respiration NAD/NADH ratio
Spare respiratory capacity

Biomarkers products, tests, panels




Note: Biomarkers that currently available on the market both for diagnostics and research are presented here. The most attention is paid to mitochondrial genetics, while mitochondrial dynamics biomarkers are less present in the market due to high complexity of the tests.

Mitochondria in Longevity: Switzerland Overview

Q3 2021



Leading Companies in Mitochondria-Longevity Industry



Switzerland has long been known as a booming BioTech hotspot in Europe that boasts many high-profile companies. Notable Swiss BioTech companies that target mitochondria for treating age-related disorders are **Santhera** and **Cellvie**.

Nanolive proposes diagnostic tools for mitochondria 3D diagnostic in living cells.

Other known companies produce dietary supplement for healthy ageing. The most impact have **Evolve** and **Amazentis**.

Swiss BioTech companies are supported by academic institutions, incubators, and accelerators. Examples include the **ETH Zurich, the University of Zurich, the University of Basel, the EPF Lausanne, StartLab, and BaseLaunch**.

Alpex Pharma



Locations: Mezzovico, Switzerland

Founded: 1983

Field: Obesity

Founder:

James C. Gale

Member of Board of Directors

Alpex Pharma is a pharmaceutical company which is active in Research & Development and Production of ODT (Orally Dispersible Tablet) called also 'fast melt' and effervescent tablets. Alpex Pharma has **developed a unique proprietary ODT covering technology**. Alpex Pharma identifies product opportunities and develops them internally in view of finding interested licensing partners.

Suprenza developed by Alex Pharma is a medication used together with diet and exercise to treat obesity. It is taken by mouth for up to a few weeks at a time, after which the beneficial effects no longer occur. It is also available as the combination phentermine/topiramate.

Amazentis



Locations: Pratteln, Switzerland

Founded: 2007

Field: Anti-ageing

Founders:

Patrick Aebischer, MD
Chairman and Co-Founder

Chris Rinsch, PhD
CEO and Co-Founder

Pierre Landolt
Co-Founder

A spin-off of EPFL, this BioTech company is developing anti-ageing products based on a novel molecule discovered in the pomegranate fruit. One of the reasons for aging is because cells struggle to recycle mitochondria efficiently, causing a buildup of cellular waste. The molecule **urolithin A** has been shown to **improve this recycling process**.

Amazentis have developed a product, which is an oral formulation of urolithin A. The company is conducting clinical trials using this molecule to target **age-related muscle decline**, or **sarcopenia**, which affects a large percentage of old people. An initial **phase I study** showed a beneficial impact on biomarkers of mitochondrial health in skeletal muscle tissue, as well as determining the optimal dosage of its product for a **future phase II trial**.

Amazentis partnered with Nestlé Health Science, which now has global rights to use the company's technology in dietary supplements, foods, and medical nutrition products.

Cellvie



Locations: Matzingen, Switzerland

Founded: 2018

Field: Mitochondria transplantation

Founders:

Alexander Schueller

Founder

Citaram Emani

CEO and Co-Founder

Pedro del Nido


Co-Founder

Cellvie, is pioneering **Therapeutic Mitochondria Transplantation**, a novel treatment approach aimed at cellular energy metabolism restoration. Cellvie is deriving medicines from cells, leveraging one of the cornerstones of evolution: mitochondria.

Mitochondria are the cell's powerhouses, and **mitochondria dysfunction** has been tied to a **host of medical conditions, including heart disease, stroke, diabetes, Parkinson's and Alzheimer's**. But mitochondria have, for the most part, eluded treatment, **Cellvie is using, a technique of augmentation and replacement to reinvigorate the cell energy** metabolism when the mitochondria are failing.

The potential of Therapeutic Mitochondria Transfer was recently demonstrated in a clinical investigation at Boston Children's Hospital. Pediatric patients on heart-lung-support after suffering a cardiogenic shock received the treatment to revitalize their heart muscle. **Cellvie is pursuing an indication in organ transplantation**, first, the FDA awarded orphan drug designation in 2020. In addition, the company has completed a new financing round raising \$5M, with Kizoo Technology Capital as the lead investor.

Evolva



Locations: Reinach,
Switzerland

Founded: 2004

Field: Anti-ageing

Founders:

Oliver Walker

CEO

Michael Malone

Vice-President

Scott Fabro

COO

Evolva focuses on producing high-value ingredients for use in health, wellness, and nutrition applications based on a solid research foundation. **The company has an R&D team of around 120 scientists working on the cutting edge of their field.**

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches. Evolva's biologists apply for the latest advances in biotechnology and science to transform fermentation into a process that can produce a various nature-based ingredients. The starting point is the biochemical pathways: these are a series of conversion steps that for example enable the plant to convert water and sunlight (or nutrients) into a specific ingredient. Then, using biotechnology, these pathways can be changed to produce the desired component in a laboratory.

Veri-te™ resveratrol is produced by Evolva. Resveratrol is a polyphenol that is found in several types of plants. Resveratrol has been shown to penetrate cells and **help rejuvenate the mitochondria, thus supporting healthier ageing.** By working at this cellular level, resveratrol can have a beneficial effect on multiple organs.

La PEAU



Locations: Geneva, Switzerland

Founded: 2001

Field: Anti-ageing

Founder:

Carla-Maria Khanjian

CEO, Co-Chairman

Irma Khanjian

President, Co-Chairman

La Peau skincare is a 3-SKU skincare line (Night, Day and Eyes) from Switzerland. Developed by Stanford University scientists, together with Geneva-based biochemists, La Peau skincare offers massive antioxidant properties. The Vitamin C contained in La Peau products, hydrates and conditions skin without irritation. Vitamin C is a major antioxidant in the body. It is well established that Vitamin C is essential for healthy skin. **The mitochondrion, in a certain way, controls collagen and elastin production.** Vitamin C helps to send the 'triggering' effect for the mitochondria to give the command to produce more collagen. This delivery system is 'bioengineered' similar to human cells: first, it allows the Vitamin C to be absorbed without being decomposed or destroyed by other biological factors; and second, it eliminates any irritation caused by the free radicals. The result is firming and glowing skin.

The mitochondria-rich cell population of the epidermis was counted and the epidermal thickness was measured after using La Peau products. **There were significant differences in the mitochondria-rich cell content and the epidermal thickness of the skin with and without La Peau products.**

Nanolive



Locations: Tolochenaz, Switzerland

Founded: 2013

Field: Mitochondria 3D diagnostic in living cells

Founders:

Yann Cotte
CEO & Founder

Fatih Toy
Co-Founder

Sebastien Equis
Co-Founder

Nanolive delivers breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive's innovative solutions combine screening, imaging, and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.

Nanolive imaging platforms allow scientists to **explore living cells in 3D without damaging mitochondria**. By delivering complete measurements and understandings on a sub-cellular scale (e.g., mitochondrial networks, stem cell differentiation), Nanolive technology allows screening across thousands of live cell populations and potential therapeutic use of those same, unperturbed cells.

Nanolive solutions **accelerate the drug discovery** and development workflows of leading biopharma companies, **transforming immuno-oncology, pathway discovery, mitochondrial & cell metabolism analysis, and sensitive cell line analytics**.

Santera



Locations: Pratteln, Switzerland

Founded: N/A

Field: Drug development

Founders:

Dario Eklund
CEO


Andrew Smith
CFO

Santera's research is focused on therapies for rare diseases and is currently focused on developing treatment options for **neuromuscular diseases**. **Duchenne muscular dystrophy** (DMD) is one of the most common and devastating types of muscular degeneration and results in progressive muscle weakness, starting at an early age. **Congenital muscular dystrophy** (CMD) is a group of inherited neuromuscular conditions that causes progressive and potentially life-threatening muscle weakness, frequently affecting newborns and children.


The mitochondria-targeted drug is idebenone (Raxone), which is developed and currently trialed by Santera Pharmaceuticals. As idebenone can protect mitochondria from oxidative damage it is expected to boost their impaired function and thus slow decline in heart function. In addition, **Raxone is a 'hybrid medicine'**. This means it is similar to a 'reference medicine' containing the same active substance, but Raxone contains idebenone at a different strength. The reference medicine for Raxone is Mnesis. Santera is developing Raxone in a third indication, **primary progressive multiple sclerosis (PPMS)**.

Investment Activity in the Industry

Top Countries by Number of Investors, % of Total



Main Type of Investors, % of Total



Switzerland is in 4th place among other world countries by the number of investors that invested **\$268M** in companies conducting Mitochondria research. Furthermore, **all investors (7 organisations)** that contribute money to Swiss BioTech companies are **Venture Capital firms**.

Fundamental Research of Mitochondrial Dysfunction

Many of the BioTechs in Switzerland are connected to **the University of Lausanne (UNIL)**, as well as the renowned **Swiss Federal Institute of Technology Lausanne (EPFL)**. BioTechs in Lausanne are particularly strong in medical applications.

The biggest Swiss pharmaceutical companies, **Nestle Health Science**, **Hoffmann la Roche** and **Novartis**, also provide fundamental research and study therapeutic targets of mitochondrial dysfunction. The main area of interest is a mechanism of age-related myopathies, cardiovascular disorders and vision loss.

Academia



Big Pharma



Key Influencers and Experts



Patrick Aebischer
Amazentis




Yann Cotte
Nanolive



Dario Eklund
Santera



James C. Gale
Alpex Pharma



Carla Khanjian
La PEAU



Vasant Narasimhan
Novartis




Chris Rinsch
Amazentis



Alexander Schueller
Cellvie



Severin Schwan
Roche



Oliver Walker
Evolve

Trends and Prospects of the Mitochondria-Longevity Industry in Switzerland

Q3 2021



Trends and Prospects

1

Prevention of Mitochondrial Ageing

Dietary supplements help rejuvenate the mitochondria and support healthier ageing in many parts of the body. Currently, the size of the dietary supplement market is estimated at **\$110M**. The main players are **Evolva** (ROS target), **Amazentis** (PINK1 target), and **Nestle** (OXPHOS regulation).

2

Treatment of Muscle & Heart Ageing

Targeting mitochondria to prevent and treat ageing of myocytes is the most popular direction among Swiss BioTech companies and R&D centres with a market size more than **\$140M**. **Santhera** is a leader which has marketed modulator of mitochondrial complex III for the treatment of muscular dystrophy. **University Hospital (Basel)** has completed **Ph-3** of clinical trial for Cytrulin- α in patients with muscle dysfunction.

3

New Tools for R&D

Changes in mitochondrial morphology are good indicators of cell health. **Nanolive** offers the only tool to **image** these organelles, their finest dynamics and interactions with other organelles (e.g., lipid droplets) **marker-free and for long periods**, enabling researchers to extract more in-depth information about their mitochondrial and cell health.

4

Brain Energy and Ageing

Swiss research suggests that changes in energy metabolism could be part of age-related neurodegenerative disorders, migraine, and brain function. **University Hospital Inselspital (Bern)** and **University Hospital (Basel)** will start two clinical trials to treat neuronal disorders.

5

Tissue Regeneration

Coenzyme Q10 (CoQ10) is a critical intermediate of the mitochondrial electron transport chain for the synthesis of adenosine triphosphate. The biological importance of CoQ10 is related to antioxidant activity, which can scavenge free radicals as well as restore the antioxidant defence system. **University of Bern** is recruiting people for new clinical trial.

6

Mitochondria Transplantation


Cellvie, a Harvard spin-off founded in the US with headquarters in Zurich, has closed a **\$5M round to prepare a clinical trial in organ** transplantation and expand rejuvenation therapies pipeline. The team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, ageing, and beyond. Cellvie is pursuing an indication in organ transplantation, first, the FDA awarded orphan drug designation in 2020.

Future Opportunities in Advancing Mitochondrial Medicine

According to the **United Mitochondrial Disease Foundation**, there are dozens of **symptoms** in almost every organ system that could be **associated with mitochondrial disease**. Some of them are age-related and can be treated by senolytic drug.

Studies indicate the ones represented by circles closest to the center are more influenced

- Age-related disorders
- Developmental disorders



Conclusions



Key Takeaways



As of 2021, the percentage of clinical trials related to mitochondrial dysfunction is **negligible compared to trials focused on other hallmarks of ageing (~3% of the total amount)**. **In Switzerland only 15 clinical trials for study of mitochondrial function are provided for the last 10 years:** 8 trials for therapeutic programmes, 3 - dietary supplements, 3 - behavioral study.



Many of the BioTech companies in the country are connected to **the University of Lausanne (UNIL)**, as well as the renowned **Swiss Federal Institute of Technology Lausanne (EPFL)**. BioTechs in Lausanne are particularly solid in medical applications. The pharmaceutical companies, **Nestle, Roche** and **Novartis**, also provide fundamental research and study therapeutic targets of mitochondrial dysfunction.



A spin-off of EPFL, **Amazentis**, is developing anti-ageing products based on a **uroolithin A**, targeting PINK1, which has been shown to improve the mitophagia process. The company is conducting clinical trials using this molecule to target **age-related muscle decline**, or **sarcopenia**, which affects many people as they grow older.



Cellvie, a Harvard spin-off founded in the US with headquarters in Zurich, pioneering **therapeutic mitochondria transplantation**. Employing proprietary preparation and delivery techniques, Cellvie is transplanting mitochondria directly into compromised cells. The company has now set out to bring it about as a new treatment modality in **ischemia-reperfusion injury, ageing, and beyond**.



Research & Development centres focus on the treatment of **muscle dysfunction, neurodegenerative disorders, obesity, wound healing**, etc. R&D centres create an important background for BioTech companies. So, the **new mitochondrial approach** in Swiss BioTech market will be intensively developed in the next few years.

Stay on Top of the Latest Intelligence

Stay on top of the latest information about Switzerland's DeepTech Industry with our analytical case studies and interactive IT platforms.

Basel Area Life Science Ecosystem

Basel Area Life Sciences Ecosystem

Landscape Overview Q3 2021

Teaser



Longevity and Precision Medicine Clinics in Switzerland

Longevity and Precision Medicine Clinics in Switzerland

Landscape Overview Q3 2021

AI Industry in Switzerland

Artificial Intelligence Industry in Switzerland

Teaser

August, 2021



Longevity Industry in Switzerland



InsurTech in Switzerland



Longevity in Switzerland Landscape overview 2019



Longevity Investment: Big Data Analytics Dashboard



Longevity Investment Big Data Analytics Dashboard

Market Intelligence

Longevity Investment Market Intelligence

Major Trends

Network Diagrams

Interactive MindMaps

Interactive Mindmaps



View More

Dashboard Parameters

DATA POINTS

814090

PERSONALITIES

16107

COMPANIES

19603

INVESTORS

9007

SECTORS

14

SUBSECTORS

140

Dynamic Industry Charts



View More

Longevity Investment Market Intelligence

SWOT Analysis

FAQ & Tutorials

Register Free Account

Send Us Feedback

Search Engine

Longevity Investment Ecosystem Investors

Investor Portfolio Search

Investor Competitors Search

Investor Search


Investor & Company Advanced Search



Find Investors

Find Companies

Competitor Search



Company Competitors

Investor Competitors

Interactive Network Diagrams



View More

Longevity Investment Ecosystem Companies

Company Investor Search

Company Competitors Search

Entrepreneur Search

Welcome There!

Aging Analytics Agency: Value Proposition

Visit Website



Aging Analytics Agency is the only specialised analytics agency in the world that focuses exclusively on the emerging Longevity Industry. They are recognised internationally as the premier analytics agency for advanced data analysis, industry reports and next-generation infographics on the topics of Aging and Longevity.

Aging Analytics Agency is focusing on three key activities:

Providing Commercial Services



Conducting customised case studies, research and analytics for internal (organizational) use, tailored to the precise needs of specific clients.

Preparing Open Access Reports

Producing regular open access and proprietary analytical case studies on the emerging topics and trends in the Longevity Industry.

Building Big Data Analytics Platforms

Offering customised analysis using specialised interactive industry and technology databases, IT-platforms and Big Data Analytics Dashboards.





AGING ANALYTICS AGENCY

E-mail: info@aginganalytics.com

Website: www.aginganalytics.com

Aging Analytics Agency (AAA) Disclaimer.

The information and opinions in this report were prepared by Aging Analytics Agency. The information herein is believed by AAA to be reliable but AAA makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. AAA may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of AAA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of AAA and are subject to change without notice. AAA has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.